Charles Schwab Investment Management Inc. Has $105.43 Million Stock Position in Insmed Incorporated (NASDAQ:INSM)

Charles Schwab Investment Management Inc. lifted its holdings in Insmed Incorporated (NASDAQ:INSM - Free Report) by 10.5% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 1,444,266 shares of the biopharmaceutical company's stock after purchasing an additional 137,670 shares during the quarter. Charles Schwab Investment Management Inc. owned about 0.81% of Insmed worth $105,431,000 as of its most recent SEC filing.

A number of other large investors have also bought and sold shares of the business. Intech Investment Management LLC acquired a new position in shares of Insmed in the third quarter valued at approximately $3,401,000. Jennison Associates LLC lifted its position in Insmed by 3.4% in the 3rd quarter. Jennison Associates LLC now owns 769,253 shares of the biopharmaceutical company's stock valued at $56,155,000 after acquiring an additional 24,973 shares in the last quarter. Commerce Bank boosted its stake in Insmed by 2.4% in the 3rd quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company's stock worth $499,000 after purchasing an additional 163 shares during the period. B. Metzler seel. Sohn & Co. Holding AG bought a new position in Insmed during the 3rd quarter worth about $767,000. Finally, Pathstone Holdings LLC raised its stake in shares of Insmed by 9.5% in the 3rd quarter. Pathstone Holdings LLC now owns 35,544 shares of the biopharmaceutical company's stock valued at $2,595,000 after purchasing an additional 3,070 shares during the period.

Insider Buying and Selling at Insmed

In other news, insider Orlov S. Nicole Schaeffer sold 37,575 shares of Insmed stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $71.50, for a total transaction of $2,686,612.50. Following the completion of the sale, the insider now owns 100,100 shares of the company's stock, valued at approximately $7,157,150. This trade represents a 27.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Michael Alexander Smith sold 27,871 shares of the company's stock in a transaction dated Friday, September 13th. The shares were sold at an average price of $74.35, for a total transaction of $2,072,208.85. Following the completion of the transaction, the insider now owns 67,856 shares in the company, valued at $5,045,093.60. This trade represents a 29.12 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 78,882 shares of company stock worth $5,765,446 over the last ninety days. Insiders own 4.60% of the company's stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on INSM shares. JPMorgan Chase & Co. upped their price objective on Insmed from $74.00 to $83.00 and gave the stock an "overweight" rating in a research report on Friday, November 22nd. Bank of America upped their price target on Insmed from $84.00 to $86.00 and gave the stock a "buy" rating in a research report on Wednesday, October 9th. TD Cowen lifted their price objective on shares of Insmed from $75.00 to $98.00 and gave the company a "buy" rating in a report on Friday, August 9th. StockNews.com lowered shares of Insmed from a "hold" rating to a "sell" rating in a research report on Friday, August 9th. Finally, Stifel Nicolaus raised their target price on shares of Insmed from $74.00 to $88.00 and gave the company a "buy" rating in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, Insmed has a consensus rating of "Moderate Buy" and a consensus target price of $83.67.

Insmed Trading Up 2.1 %

Insmed stock opened at $75.68 on Wednesday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. The stock has a 50-day simple moving average of $72.05 and a 200 day simple moving average of $66.93. The stock has a market capitalization of $13.54 billion, a P/E ratio of -13.64 and a beta of 1.12. Insmed Incorporated has a 52 week low of $21.92 and a 52 week high of $80.53.

Insmed (NASDAQ:INSM - Get Free Report) last posted its earnings results on Thursday, October 31st. The biopharmaceutical company reported ($1.27) earnings per share for the quarter, missing analysts' consensus estimates of ($1.19) by ($0.08). The company had revenue of $93.40 million during the quarter, compared to analyst estimates of $93.36 million. During the same quarter in the previous year, the firm earned ($1.10) earnings per share. The company's revenue was up 18.1% compared to the same quarter last year. Analysts expect that Insmed Incorporated will post -5.42 earnings per share for the current year.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.